A detailed history of Baker Avenue Asset Management, LP transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Baker Avenue Asset Management, LP holds 673 shares of REGN stock, worth $498,026. This represents 0.02% of its overall portfolio holdings.

Number of Shares
673
Holding current value
$498,026
% of portfolio
0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$1024.09 - $1201.76 $689,212 - $808,784
673 New
673 $707,000
Q3 2023

Nov 14, 2023

BUY
$692.45 - $844.37 $692 - $844
1 Added 2.33%
44 $36,000
Q2 2023

Aug 11, 2023

SELL
$700.03 - $830.35 $520,122 - $616,950
-743 Reduced 94.53%
43 $30,000
Q1 2023

May 15, 2023

BUY
$680.49 - $826.97 $72,131 - $87,658
106 Added 15.59%
786 $645,000
Q4 2022

Feb 13, 2023

BUY
$705.89 - $766.39 $480,005 - $521,145
680 New
680 $490,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $79.3B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Baker Avenue Asset Management, LP Portfolio

Follow Baker Avenue Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Avenue Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Avenue Asset Management, LP with notifications on news.